Abstract
Heat shock protein 90 (Hsp90) is a molecular chaperone involved in the trafficking of proteins in the cell. Under stressful conditions, Hsp90 stabilizes its client proteins and provides protection to the cell against cellular stressors such as in cancer cells. Disruption of Hsp90 leads to client protein degradation and often cell death. As Hsp90 has been found to be either overexpressed or constitutively more active in cancer cells, inhibitors of Hsp90 may have cancer cell selectivity. The N-terminal inhibitors, geldanamycin and radiciol, were the first two described inhibitors of Hsp90, but were not clinically useful. Subsequent analogues—17 allylamino-17demethoxygeldanamycin and 17 dimethylaminoethylamino-17-demethoxygeldanamycin—were found to be more clinically appropriate and have been studied in a number of clinical trials since 1999. In addition, to the N-terminal site of Hsp90, the C-terminal site appears to be another target for inhibition of Hsp90. More recently, inhibitors of the C terminus of Hsp90 have been developed and studied in vitro with promising results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Garnier C, Lafitte D, Tsvetkov PO, Barbier P, Leclerc-Devin J, et al.: Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J Biol Chem 2002, 277:12208–12214.
Yu XM, Shen G, Neckers L, et al.: Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc 2005, 127:12778–12779.
Zhang H, Burrows F: Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004, 82:488–499.
Chiosis G, Vlenchik M, Kim J, Solit D: Hsp90: the vulnerable chaperone. Drug Discuss Today 2004, 9:881–888.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57–70.
•• Mahalingam D, Swords R, Carew JS, et al.: Targeting HSP90 for cancer therapy. Br J Cancer 2009, 100:1523–1529. This review provides a comprehensive list of the multiple client proteins of Hsp90 and their relationship to their oncogenic pathway.
• Donnelly A, Blagg BSJ: Novobiocin and additional inhibitors of the Hsp90 C-Terminal nucleotide-binding pocket. Curr Med Chem 2008, 15:2702–2717. This article offers an excellent review of the structure and function of Hsp90.
Bagatell R, Whitesell L: Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004, 3:1021–1030.
Kamal A, Thao L, Sensintaffar J, et al.: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407–410.
Neckers L, Lee YS. Cancer: the rules of attraction. Nature 2003, 425:357–359.
Whitesell L, Mimnaugh EG, De Costa B, et al.: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994, 91:8324–8328.
Uehara Y: Natural product origins of Hsp90 inhibitors. Curr Cancer Drug Targets 2003, 3:325–330.
Conde R, Belak ZR, Nair M, et al.: Modulation of Hsf1 activity by novobiocin and geldanamycin. Biochem Cell Biol 2009, 87:845–851.
•• Kim YS, Alarcon Sv, Lee S, et al.: Update on Hsp90 Inhibitors in clinical trial. Curr Top Med Chem 2009, 9:1479–1492. This paper comprehensively details the clinical trials and their results for the Hsp90 inhibitors.
Ronnen EA, Kondagunta GV, Ishill N, et al.: A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006, 24:543–546.
Heath E, Hillman D, Vaishampayan U, et al.: A phase II trial of 17-Allylamino-17-Demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 2005, 4:138–141.
Solit D, Osman I, Polsky D, et al.: Phase II trial of 17-Allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008, 14:8302–8307.
Tse A, Klimstra D, Gonen M, et al.: A phase I dose-escalation study of ironotecan in combination with 17-Allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 2008, 14:6704–6711.
Ramalingam S, Egorin M, Ramanathan R, et al.: A phase I study of 17-Allylamino-17-Demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 2008, 14:3456–3461.
Richardson PG, Chanan-Khan A, Lonial S, et al.: Tanespimycin + bortezomib in multiple myeloma: confirmation of the recommended dose using a novel formulation [abstract 1165]. Presented at the American Society of Hematology Annual Meeting. Atlanta, GA; December 8–11, 2007.
Modi S, Stopeck A, Gordon M, et al.: Combination of trastuzumab and tanespimycin is safe and active in trastuzumab refractory HER-2-overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007, 25:5410–5417.
Doate H, Cerna D, Burgan WE, et al.: ErbB3 expression predicts tumor cell radiosnesitization induced by Hsp90 inhibition. Cancer Res 2005, 65:6967–6969.
Harashima K, Akimoto T, Nonaka T, et al.: Heat shock protein 90 (Hsp90) chaperone coplex inhibitor, radiciol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor. Int J Radiat Biol 2005, 81:63–76.
• Camphausen K, Tofilon PJ: Inhibition of Hsp90: A multitarget approach to radiosensitization. Clin Cancer Res 2007, 13:4326–4330. This article provides an excellent review of the literature to date regarding the use of Hsp90 inhibitors as radiosensitizers.
• Burlison JA, Avila C, Vielhauer G, et al.: Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J Org Chem 2008, 73:2130–2137. This novel paper demonstrates the efficacy of a novobiocin analogue in in vitro studies and confirms the degradation of client proteins of Hsp90 in these cells.
Sreedhar AS, Soti, Sermely P: Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta 2004, 1697:233–242.
Rosenhagen MC, Soti C, Schmidt U, et al.: The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Mol Endocrinl 2003, 17:1991–2001.
Palermo CM, Westlake CA, Gasiewicz TA: Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein. Biochemistry 2005, 44:5041–5052.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Holzbeierlein, J.M., Windsperger, A. & Vielhauer, G. Hsp90: A Drug Target?. Curr Oncol Rep 12, 95–101 (2010). https://doi.org/10.1007/s11912-010-0086-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11912-010-0086-3